Novo nordisk a/s today
Novo Nordisk a/s.
- 52-week range
- $ 77.82
▼
$ 148.15
- Dividend yield
- 0.92%
- P/e ratio.
- 23.69
- Value is valuable
- $ 145.25
Promotions to reduce weight and medicine for diabetes novo nordisk NYSE: NVO Over the past 52 weeks, have fallen over the past 52 weeks. Promotions decreased by 34% for this period as of February 13. The New Year did not provide a respite, and the shares decreased by more than 8%. Promotions are currently traded less than 1% higher than their 52-week minimum.
This big drop raises the question: have the shares of this pharmaceutical reserve become? Some analysts with large banks give a loud “yes” to this issue. I will analyze the key indicators from the recent financial report of the company than expected, along with other important events to give my gaze.
New Nordisk reports high income and growth of profit in 4 quarters.
In the fourth quarter, revenue and net profit in Novo both solidly increased by 30% and 29%, respectively. The well -known drug of the company Otrotheka, used to treat type 2 diabetes, showed a moderate increase in sales by 12%. However, this is much slower compared to 60% of Eli Lilly growth NYSE: Lly A competing drug, Munjaro, achieved. On the other hand, Wegovy sales were bubbles growing by 107%. This is the same drug as the hull, but it treats obesity.
An increase in income from a non -American level by 329% helped to achieve this huge general growth. This is one of the areas where Novo, of course, has an advantage over Lilly. The competing drug Lilly against Vegovy, known as Zepbound, has not yet recorded any sales outside the United States. Compared to the total sales growth of 26% in 2024, NOVO predicts an increase of 16% to 24% in 2025.
On the horizon: production is increasing and the Kagrisem dilemma
In general, NOVO has two especially large initiatives for 2025. Firstly, there is an opportunity to provide more active ingredients in the OTO Zempe and Vegovy, half -Glutids. Semglutid remains in the list of lack of management control controls (FDA). This limits the growth of sales, allowing composers, such as Him & Hers Health NYSE: Hims Sell a product meanwhile. FDA took the competing formula Lilly, Tirzepatide, outside the list in October 2024. Novo invested billions in an increase in production. The company has achieved significant success in raising supplies. He plans to serve 30% more patients in 2025 by expanding operations.
The second task is to clarify the details of the upcoming weight loss and treatment of diabetes, CAGRISEMA. The injection showed a slightly higher weight loss, adjusted placebo, is 20.4% compared with 20.1% Zepbound. The results sent the NOVO shares, which fell in December 2024, since they could not show significantly higher weight loss than Zepbound.
The abnormal part of the study was that patients could reduce their dose if they need it. It is curious that patients who completed treatment at a lower dose lost 3% more weight than those who finished at a higher dose. Many consider this to be contradictory, since higher doses often lead to higher weight loss. NOVO initiates a new test, which will begin in the first half of 2025. It seems that the duration of treatment and a change in dosing over time can affect effectiveness. The current results show that the adapted dosage for each patient can increase the efficiency of CAGRISEMA.
Ultimately, it seems likely to me that the potential Cagisema market is underestimated. There is an important reason to believe that the drug works very well for certain patients, as well as the angle that can be based on. However, further results will have to be released to confirm this.
Analysts ratings and a lower rating compared to Lilly suggest an increase
Novo Nordisk A/S Marketrank ™ Promotion Analysis
- General market ™
- 92nd percentile
- Analyst rating
- Moderate purchase
- Breaking/disadvantage
- 86.4% growth
- Short level of interest
- Healthy
- The power of dividends
- Weak
- Environmental assessment
- N/a
- Mood news
- 0.45
- Insider trade
- N/a
- Professe Earnings growth
- 20.73%
See full analysis
Marketbeat has not tracked updates of target analytical prices for Novo Nordisk from the moment of profit. These ratings can sometimes be difficult to find, because Novo is a Danish company. Nevertheless, two updates specified in the Danish currency provide the average target price of 988 of the Danish Crohn (DKK), approximately $ 136.70. Compared to 566 prices DKK (about $ 78.34) shares (about $ 78.34), this goal implies a huge increase of almost 75%. Currency fluctuations and other factors will lead to differences in losses and potential indicators compared to the American depository receipt of Novo (ADR).
Although I think this amount of optimistic growth, the Novo shares seem somewhat underestimated. Its ratio of price to profit (P/E) is 21X by about 45% lower than 38 times Lilly. In my opinion, both provide reasonable ways to play in this space for various reasons. Lilly is a higher growth, while the comparative assessment of Novo and suppressed moods offer growth.
Before considering Novo Nordisk A/S, you will want to hear it.
Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their clients to buy now before a wider market is won … and Novo Nordisk A/S was not on the list.
While Novo Nordisk A/S currently has a “moderate purchase” rating among analysts, analysts with the highest rating believe that these five promotions are better buying.
View five shares here
Marketbeat analysts have just released their five best short plays for February 2025. Find out what shares have the shortest interest and how to trade them. Enter your email address to see which companies compiled a list.
Get this free report